AIM ImmunoTech Inc. (AIM) News
Filter AIM News Items
AIM News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest AIM News From Around the Web
Below are the latest news stories about AIM IMMUNOTECH INC that investors may wish to consider to help them evaluate AIM as an investment opportunity.
AIM ImmunoTech Provides Update Regarding Annual MeetingOCALA, Fla., November 28, 2023--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023. The purpose of the adjournment is to provide the Delaware Court of Chancery (the "Court") with sufficient time to issue a ruling with respect to the |
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. PatentsExtends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise |
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsNo severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed treatment in the Company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”). AIM Chief Executive Officer Thomas K. Equels commented, “With dosing now complete, our AMP-518 focus t |
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed ChangeTed D. Kellner, Todd Deutsch and Robert L. Chioini (collectively, the "Kellner Group") today issue the following statement in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE American: AIM) and create value for stockholders. The Kellner Group is convinced that they have the experience to make AIM successful and that an immediate change in directors on the AIM board at this year's annual meeting is absolutely necess |
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15th at 8:30 AM ET OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Com |
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast CancerData published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed |
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and WebcastOCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial results on Wednesday, November 15, 2023 at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may acces |
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian CancerData presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study ongoing; topline interim results expected before year end OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to |
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to ShareholdersOCALA, Fla., November 06, 2023--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the Company has filed its Definitive Proxy Statement in connection with AIM’s upcoming 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting"), scheduled for December 1, 2023. The Company also sent a letter to shareholders in connection with the Annual Meeting. |
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the S |